Analysis on the compatibility rules and mechanism of formulae treatment for COVID-2019 based on the TCM inheritance assistance system and network pharmacology

Background:On December 8,2019,Wuhan City,Hubei Province,a new type of coronavirus disease 2019(COVID-2019)was firstly discovered,and COVID-2019 spread rapidly in China.The number of confirmed cases in various provinces and cities rose sharply in China.In clinical treatment,Chinese medicine treatment showed significant efficacy.Since the outbreak,the National Health Commission(NHS)of China has issued seven editions of the“Pneumonitis Diagnosis and Treatment Program for COVID-2019”,at the same time,most provincial health boards and the Chinese Medicine Administration had also released information on the prevention and control scheme of COVID-2019 by Chinese medicine.The purpose of this study is to explore the compatibility rules of the main drugs in the prescription and the potential mechanism on COVID-2019 pneumonia,in order to provide reference for clinical research and new drug development of COVID-2019.Methods:This article uses the TCM inheritance assistance system and network pharmacology BATMAN-TCM online analysis system to collect and summarize the national“Pneumonitis Diagnosis and Treatment Program for COVID-2019(trial version sixth)”and formulae for adult treatment from the TCM prevention program of 23 provinces and cities.Results:We found that the most formulae for the treatment of COVID-2019 were modified on the basis of Maxing Shigan decoction and the top 5 high-frequencyn drugs are Xingren(Armeniacae semen amarum),Mahuang(Ephedrae herba),Gancao(Glycyrrhizae radix et rhizoma),Shigao(Gypsum fibrosum),and Haungqin(Radix scutellariae).High frequency traditional Chinese medicines are mainly used for relieving the symptoms,clearing away heat,eliminating dampness,resolving phlegm,relieving cough and asthma,promoting water and dampness,and tonifying deficiency.Warm medicine and bitter medicine are the most frequently used drugs in four Qi attribute and five flavor attribute,respectively.Most of drugs are belong to lung,stomach and spleen channel.Mahuang(Ephedrae herba),Xingren(Armeniacae semen amarum),Gancao(Glycyrrhizae radix et rhizoma),Shigao(Gypsum fibrosum),Cangzhu(Atractylodis rhizama)and Huoxiang(Pogostemonis herba)are the core drugs for treating COVID-2019.The TTD disease enrichment,target and signal transduction pathways of the six drugs showed that pneumonia and asthma were most closely related to COVID-2019.And the inflammatory reaction-related pathways may be the main pathways through which these drugs function.Conclusions:The modified Maxing Shigan decoction is the main prescription for the treatment of COVID-2019.The Xingren(Armeniacae semen amarum),Gancao(Glycyrrhizae radix et rhizoma),Shigao(Gypsum fibrosum),Cangzhu(Atractylodis rhizama)and Huoxiang(Pogostemonis herba)have certain theoretical and experimental basis for the treatment of COVID-2019 through network pharmacology analysis,but further experiments are needed to verify the effects.

The law of the prescription for non-alcoholic steatohepatitis: a data mining analysis

Objective:This study aimed to explore the law of the prescription for non-alcoholic steatohepatitis and provide ideas for the clinical application.Methods:This study searched CNKI,Wanfang,CBM,VIP,Web Of Science,PubMed,Elsevier to identify the studies published in nearly three years.The Chinese Medicine Heritage Supporting Platform(V2.5)was used to analyze traditional Chinese medicines used in the treatment of nonalcoholic steatohepatitis prescriptions and their combination rules,extract core combinations to form a new formula.Results:A total of 58 commonly used prescriptions for the treatment of non-alcoholic steatohepatitis were retrieved,including 96 flavors of traditional Chinese medicine.Data mining showed that Chinese medicine with frequency≥6 had a total of 21 flavors,and common pairs of drugs and 26 pairs were used to treat nonalcoholic steatohepatitis.The core drug combination was 6 pairs and evolved into a new party with 3 pairs.Conclusion:The traditional Chinese medicine inheritance platform system has important value for the clinical trial of traditional Chinese medicine for the treatment of nonalcoholic steatohepatitis.The new evolution of the Chinese medicine provides a new idea for the clinical treatment of non-alcoholic steatohepatitis.